Avacta Group plc, a life sciences company focused on targeted cancer treatments and diagnostics, will be presenting two posters at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. The first poster will showcase AVA3996, a novel pre|CISION™ medicine that targets a warhead to the tumor microenvironment via Fibroblast Activation Protein (FAP) mediated cleavage to elicit tumor cell kill. The second poster will present AVA032, an anti-PD-L1 Affimer® fused to IL-15, which exhibits potent anti-tumor activity. Dr. Fiona McLaughlin, Chief Scientific Officer of Avacta, stated that the data to be presented demonstrates the potential of their therapeutic platforms to generate high-value clinical assets. AVA3996, based on the pre|CISION™ technology, shows targeted killing of cancer cells in vitro and reduces systemic toxicity associated with this class of drug. AVA032, an anti-PD-L1 Affimer® fused to IL-15, stimulates a potent immune response and reverses the immunosuppressive tumor microenvironment. The posters will be available to view following the conference on Avacta's website.